Novo Nordisk wins FDA green light for ‘holy grail’ diabetes drug Rybelsus
Game on. Friday, the FDA approved Novo Nordisk’s Rybelsus—or, as industry watchers know it, oral semaglutide—to control blood sugar in Type 2 diabetes patients. And with the drug boasting stellar data and head-to-head study wins against top products in the field, the green light is expected to majorly shake things up. “This ability to now… Read More »